NVCR Stock Plummets 37% After Its Ovarian Cancer Treatment Fails – Investor's Business Daily
Business News
- NVCR Stock Plummets 37% After Its Ovarian Cancer Treatment Fails Investor’s Business Daily
- Novocure stock falls as Phase 3 TTFieds trial fails Seeking Alpha
- Novocure’s tumor-treating electric fields fail phase 3 trial in ovarian cancer FierceBiotech
- Novocure Provides Update on Phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 Trial Evaluating Tumor Treating Fields Therapy in Platinum-resistant Ovarian Cancer Business Wire
- NovoCure (NASDAQ:NVCR) Nosedives on Disappointing Phase 3 Results – TipRanks.com TipRanks
- View Full Coverage on Google News
Source: Business News